Natural Alternatives International and CarnoSyn庐 Brands聽Publish Clinical Research Demonstrating 罢谤颈叠蝉测苍鈩� Delivering聽Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination
Natural Alternatives International (NAII) and CarnoSyn庐 Brands have published positive clinical trial results for 罢谤颈叠蝉测苍鈩�, their new encapsulated low-dose 尾-alanine complex. The study, published in Food Hydrocolloids for Health, demonstrated that 罢谤颈叠蝉测苍鈩� achieved 4.5-fold higher plasma 尾-alanine levels compared to conventional 尾-alanine supplementation.
The randomized, double-blind study revealed that a 400mg dose of 罢谤颈叠蝉测苍鈩� outperformed both 400mg and 1200mg doses of conventional beta-alanine. Notably, 罢谤颈叠蝉测苍鈩� eliminated paresthesia, a common side effect, scoring 0.62 on the Visual Analogue Score compared to 2.02 and 4.01 for conventional doses.
The patent-pending formulation uses proprietary Hydro Oleo technology, enabling absorption through multiple pathways including direct cellular uptake and gastrointestinal routes. The product aims to improve muscle vitality, working capacity, and cognitive performance, targeting active aging populations, GLP-1 users, and those following plant-based diets.
Natural Alternatives International (NAII) e CarnoSyn庐 Brands hanno pubblicato risultati positivi di studi clinici per 罢谤颈叠蝉测苍鈩�, il loro nuovo complesso di 尾-alanina a bassa dose incapsulato. Lo studio, pubblicato su Food Hydrocolloids for Health, ha dimostrato che 罢谤颈叠蝉测苍鈩� ha raggiunto livelli plasmatici di 尾-alanina 4,5 volte superiori rispetto alla supplementazione convenzionale di 尾-alanina.
Lo studio randomizzato in doppio cieco ha rivelato che una dose di 400mg di 罢谤颈叠蝉测苍鈩� ha superato sia le dosi di 400mg che di 1200mg di 尾-alanina convenzionale. 脠 importante notare che 罢谤颈叠蝉测苍鈩� ha eliminato la parestesia, un effetto collaterale comune, ottenendo un punteggio di 0,62 sulla Scala Analogica Visiva rispetto a 2,02 e 4,01 per le dosi convenzionali.
La formulazione in attesa di brevetto utilizza una tecnologia proprietaria chiamata Hydro Oleo, che consente l'assorbimento attraverso molteplici vie, inclusi l'assorbimento cellulare diretto e le vie gastrointestinali. Il prodotto mira a migliorare la vitalit脿 muscolare, la capacit脿 di lavoro e le prestazioni cognitive, rivolgendosi a popolazioni attive in fase di invecchiamento, utenti di GLP-1 e coloro che seguono diete a base vegetale.
Natural Alternatives International (NAII) y CarnoSyn庐 Brands han publicado resultados positivos de ensayos cl铆nicos para 罢谤颈叠蝉测苍鈩�, su nuevo complejo encapsulado de 尾-alanina en baja dosis. El estudio, publicado en Food Hydrocolloids for Health, demostr贸 que 罢谤颈叠蝉测苍鈩� alcanz贸 niveles plasm谩ticos de 尾-alanina 4.5 veces m谩s altos en comparaci贸n con la suplementaci贸n convencional de 尾-alanina.
El estudio aleatorizado y doble ciego revel贸 que una dosis de 400mg de 罢谤颈叠蝉测苍鈩� super贸 tanto las dosis de 400mg como de 1200mg de 尾-alanina convencional. Notablemente, 罢谤颈叠蝉测苍鈩� elimin贸 la parestesia, un efecto secundario com煤n, obteniendo una puntuaci贸n de 0.62 en la Escala Anal贸gica Visual en comparaci贸n con 2.02 y 4.01 para las dosis convencionales.
La formulaci贸n pendiente de patente utiliza una tecnolog铆a propietaria llamada Hydro Oleo, que permite la absorci贸n a trav茅s de m煤ltiples v铆as, incluyendo la captaci贸n celular directa y las rutas gastrointestinales. El producto tiene como objetivo mejorar la vitalidad muscular, la capacidad de trabajo y el rendimiento cognitivo, dirigi茅ndose a poblaciones activas en envejecimiento, usuarios de GLP-1 y aquellos que siguen dietas basadas en plantas.
雮挫稊霟� 鞏柬劙雱堩嫲敫岇姢 鞚疙劙雮挫厰雱� (NAII)鞕� 旃措ゴ雲胳嫚庐 敫岆灉霌滊姅 韸鸽Μ敫岇嫚鈩�鞚� 旮嶌爼鞝侅澑 鞛勳儊 鞁滍棙 瓴瓣臣毳� 氚滍憸頄堨姷雼堧嫟. 鞚措姅 攴鸽摛鞚� 靸堧鞖� 旌§姁頇旊悳 鞝�鞖╇焿 尾-鞎岆澕雼� 氤淀暕觳挫瀰雼堧嫟. Food Hydrocolloids for Health鞐� 氚滍憸霅� 鞚� 鞐瓣惮電� 韸鸽Μ敫岇嫚鈩㈧澊 旮办〈 尾-鞎岆澕雼� 氤挫订鞝滌棎 牍勴暣 4.5氚� 雴掛潃 順堨灔 尾-鞎岆澕雼� 靾橃箻毳� 雼劚頄堨潓鞚� 氤挫棳欤检棃鞀惦媹雼�.
氍挫瀾鞙� 鞚挫 毵龟瞼 鞐瓣惮 瓴瓣臣, 400mg鞚� 韸鸽Μ敫岇嫚鈩㈧澊 旮办〈 尾-鞎岆澕雼岇潣 400mg 氚� 1200mg 鞖╇焿氤措嫟 鞖办垬頃� 靹彪姤鞚� 氤挫榾鞀惦媹雼�. 韸鬼瀳, 韸鸽Μ敫岇嫚鈩㈧潃 鞚茧皹鞝侅澑 攵�鞛戩毄鞚� 臧愱皝鞚挫儊(paresthesia)鞚� 鞝滉卑頃橃棳 牍勳＜鞏� 鞎勲偁搿滉犯 鞀れ綌鞏挫棎靹� 0.62毳� 旮半頄堨溂氅�, 鞚措姅 旮办〈 鞖╇焿鞚� 2.02 氚� 4.01瓿� 牍勱祼霅╇媹雼�.
韸鬼棃 於滌洂 欷戩澑 鞚� 鞝滍槙鞚� 霃呾敖鞝侅澑 Hydro Oleo 旮办垹鞚� 靷毄頃橃棳 歆侅爲 靹疙彫 頋§垬 氚� 鞙勳灔甏� 瓴诫毳� 韽暔頃� 鞐煬 瓴诫毳� 韱淀暣 頋§垬臧� 臧�電ロ暕雼堧嫟. 鞚� 鞝滍拡鞚� 攴检湣 頇滊牓, 鞛戩梾 電ル牓 氚� 鞚胳 靹彪姤鞚� 臧滌劆頃橂姅 瓴冹潉 氇╉憸搿� 頃橂┌, 頇滊彊鞝侅澑 雲疙檾 鞚戈惮, GLP-1 靷毄鞛� 氚� 鞁濍 旮半皹 鞁濍嫧鞚� 霐半ゴ電� 靷瀸霌れ潉 雽�靸侅溂搿� 頃╇媹雼�.
Natural Alternatives International (NAII) et CarnoSyn庐 Brands ont publi茅 des r茅sultats positifs d'essais cliniques pour 罢谤颈叠蝉测苍鈩�, leur nouveau complexe de 尾-alanine encapsul茅 脿 faible dose. L'茅tude, publi茅e dans Food Hydrocolloids for Health, a d茅montr茅 que 罢谤颈叠蝉测苍鈩� atteignait des niveaux plasmatiques de 尾-alanine 4,5 fois plus 茅lev茅s par rapport 脿 la suppl茅mentation conventionnelle en 尾-alanine.
L'茅tude randomis茅e en double aveugle a r茅v茅l茅 qu'une dose de 400mg de 罢谤颈叠蝉测苍鈩� surpassait 脿 la fois les doses de 400mg et de 1200mg de 尾-alanine conventionnelle. Il est 脿 noter que 罢谤颈叠蝉测苍鈩� a 茅limin茅 la paresth茅sie, un effet secondaire courant, avec un score de 0,62 sur l'茅chelle analogique visuelle, contre 2,02 et 4,01 pour les doses conventionnelles.
La formulation en attente de brevet utilise une technologie propri茅taire appel茅e Hydro Oleo, permettant l'absorption par plusieurs voies, y compris l'absorption cellulaire directe et les voies gastro-intestinales. Le produit vise 脿 am茅liorer la vitalit茅 musculaire, la capacit茅 de travail et les performances cognitives, en ciblant les populations vieillissantes actives, les utilisateurs de GLP-1 et ceux qui suivent des r茅gimes 脿 base de plantes.
Natural Alternatives International (NAII) und CarnoSyn庐 Brands haben positive Ergebnisse klinischer Studien f眉r 罢谤颈叠蝉测苍鈩�, ihren neuen verkapselten Niedrigdosis-尾-Alanin-Komplex, ver枚ffentlicht. Die Studie, die in Food Hydrocolloids for Health ver枚ffentlicht wurde, zeigte, dass 罢谤颈叠蝉测苍鈩� 4,5-mal h枚here Plasmaspiegel von 尾-Alanin im Vergleich zur herk枚mmlichen 尾-Alanin-Supplementierung erreichte.
Die randomisierte, doppelblinde Studie ergab, dass eine Dosis von 400mg 罢谤颈叠蝉测苍鈩� sowohl die 400mg- als auch die 1200mg-Dosen von herk枚mmlichem 尾-Alanin 眉bertraf. Auff盲llig ist, dass 罢谤颈叠蝉测苍鈩� die Paresthesie, eine h盲ufige Nebenwirkung, beseitigte und einen Wert von 0,62 auf der visuellen Analogskala erzielte, verglichen mit 2,02 und 4,01 f眉r herk枚mmliche Dosen.
Die patentierte Formulierung verwendet eine propriet盲re Hydro Oleo-Technologie, die die Absorption 眉ber mehrere Wege erm枚glicht, einschlie脽lich der direkten Zellaufnahme und der gastrointestinalen Routen. Das Produkt zielt darauf ab, die MuskelVitalit盲t, die Arbeitskapazit盲t und die kognitiven Leistungen zu verbessern und richtet sich an aktive 盲ltere Menschen, GLP-1-Nutzer und Personen, die pflanzenbasierte Di盲ten einhalten.
- Clinical trial proves superior efficacy of new 罢谤颈叠蝉测苍鈩� product
- 4.5x higher bioavailability vs conventional beta-alanine
- Patent-pending technology eliminates side effects
- Effective at lower doses (400mg vs 1200mg)
- None.
Insights
Natural Alternatives International's announcement of positive clinical trial results for 罢谤颈叠蝉测苍鈩� represents a significant product advancement that could strengthen the company's market position in the nutritional supplements sector. The clinical validation published in a peer-reviewed journal establishes scientific credibility for NAI's proprietary Hydro Oleo technology, potentially creating a competitive moat through patent protection.
The demonstrated 4.5-fold increase in bioavailability compared to conventional beta-alanine products is particularly noteworthy as it enables effective supplementation at lower doses鈥攁 key differentiator that could drive premium pricing and improved margins. More importantly, the elimination of paresthesia (the tingling sensation typically associated with beta-alanine) addresses a major consumer pain point that has historically product adherence and repeat purchases.
NAI appears strategically positioned to target multiple growing market segments with this innovation, including the lucrative active aging demographic, the rapidly expanding GLP-1 user base (which needs nutritional support during weight loss), and the growing plant-based consumer segment. This multi-market approach could drive revenue diversification and reduce segment-specific risks.
The timing of this announcement suggests NAI is reinforcing its innovation pipeline to investors while demonstrating its ability to develop scientifically validated premium ingredients鈥攃ritical for a smaller player competing against larger supplement manufacturers. Investors should monitor whether this translates to improved sales performance in upcoming quarters or potential licensing opportunities for the proprietary technology.
The clinical validation of 罢谤颈叠蝉测苍鈩� represents a meaningful scientific advancement in beta-alanine supplementation. Beta-alanine's primary function is increasing muscle carnosine levels, which buffers lactic acid buildup during exercise鈥攂ut its effectiveness has been consistently by the paresthesia side effect that discourages consistent usage.
What makes these results particularly significant is the dual improvement achieved: substantially higher bioavailability (4.5-fold increase) while simultaneously eliminating the limiting side effect. This is rare in supplement development, where improvements in potency typically exacerbate side effects rather than eliminate them.
The study design follows proper scientific methodology鈥攔andomized, double-blind, crossover鈥攚ith both subjective (Visual Analogue Score) and objective measurements. The VAS score of 0.62 for 罢谤颈叠蝉测苍鈩� versus 4.01 for high-dose conventional beta-alanine clearly quantifies the user experience improvement. This could dramatically increase consumer compliance and long-term supplementation success.
NAI's targeting of specific demographics is scientifically sound. The active aging population experiences natural carnosine depletion; GLP-1 users often lose muscle mass during rapid weight loss; and plant-based dieters typically consume less beta-alanine from food sources. The encapsulation technology enabling "multiple absorption pathways" suggests improved cellular uptake efficiency, which could make the supplement more effective even at the reduced 400mg dosage.
The publication in Food Hydrocolloids for Health, while not among the highest-impact journals, still provides peer-reviewed validation that exceeds the minimal regulatory requirements for supplement claims, potentially allowing for stronger marketing positions and clinical applications.
CARLSBAD, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. (NAI) and CarnoSyn庐 Brands today announced the publication of positive clinical trial results in the journal showing that 罢谤颈叠蝉测苍鈩� supplementation led to significantly greater bioavailability and efficiency of beta-alanine along with the elimination of paresthesia, a common beta-alanine side effect.
Study Highlights:
- 罢谤颈叠蝉测苍鈩� is an encapsulated low-dose 尾-alanine complex.
- 罢谤颈叠蝉测苍鈩� increased plasma 尾-alanine 4.5-fold compared to conventional 尾-alanine.
- 罢谤颈叠蝉测苍鈩� achieved high plasma concentrations without the sensation of paresthesia.
罢谤颈叠蝉测苍鈩� is a carnosine booster derived from CarnoSyn庐聽beta-alanine and formulated using proprietary Hydro Oleo technology. This patent-pending formulation provides higher bioavailability and higher potency, enabling efficacious dosages at lower volumes while effectively eliminating paresthesia. The advanced formulation enables absorption through multiple pathways, including direct cellular uptake and traditional gastrointestinal routes, allowing for superior delivery at both the cellular and systemic levels. Adequate availability of beta-alanine is critical for maintaining muscle and promoting cognitive well-being. Efficacious doses of beta-alanine are often associated with harmless but generally uncomfortable symptoms of paresthesia, discouraging adherence to supplementation.
This study aimed to evaluate the bioavailability, pharmacokinetics, and tolerability of a 400 mg Hydro Oleo encapsulated beta-alanine complex (罢谤颈叠蝉测苍鈩�) specifically designed to reduce paresthesia. A randomized, double-blind, single-dose, three-treatment, three-way crossover oral bioavailability study was conducted in healthy older adults under fasting conditions. The study compared 罢谤颈叠蝉测苍鈩� with low (400 mg) and high (1200 mg) doses of conventional beta-alanine. 罢谤颈叠蝉测苍鈩� (400 mg) achieved a nearly 4.5-fold and 1.3-fold increase in circulating beta-alanine plasma concentrations compared to 400 mg and 1200 mg of conventional beta-alanine, respectively.
Using metrics such as the Visual Analogue Score (VAS) and Qualitative Light Symptoms Inventory (QLSI), sensory side effects were assessed. No paresthesia or adverse effects were reported in the 罢谤颈叠蝉测苍鈩� group, while the conventional beta-alanine groups exhibited increasing paresthesia with dose. 罢谤颈叠蝉测苍鈩� (400 mg beta-alanine) recorded a VAS score of 0.62 (indicating almost absent symptoms), whereas conventional 尾-alanine (400 mg) and conventional 尾-alanine (1200 mg) scored 2.02 and 4.01 respectively. These results highlight the reduced sensory discomfort in the 罢谤颈叠蝉测苍鈩� group, despite its higher bioavailability.
鈥淭he 罢谤颈叠蝉测苍鈩� clinical trial results clearly showed the elimination of paresthesia and an increased pharmacokinetic efficiency, confirming enhanced delivery and exceptional bioavailability,鈥� said Ken Wolf, President and COO of Natural Alternatives International. 鈥淲ith its advanced Hydro Oleo technology and carnosine-boosting effects, 罢谤颈叠蝉测苍鈩� provides scientifically proven claims to improve muscle vitality, muscle working capacity, and cognitive performance. It truly sets a new standard in beta-alanine supplementation and helps fill the gap for healthy aging and wellness solutions鈥攅specially for the active aging population, GLP-1 users, and those with plant-based diets.鈥�
About CarnoSyn庐聽Brands:
CarnoSyn庐聽Brands features three clinically studied, patented and patent pending ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn庐聽instant release beta-alanine powder, SR CarnoSyn庐聽sustained release beta-alanine tablets, and 罢谤颈叠蝉测苍鈩� powder. In 2019, CarnoSyn庐 beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status. SR CarnoSyn庐, an advanced delivery form of CarnoSyn庐, received GRAS affirmation in 2017. The new 鈥減aresthesia-free鈥� 罢谤颈叠蝉测苍鈩� powder allows NAI to broaden their product offerings within the dietary supplement category, medical food and other fortified food products. To learn more about CarnoSyn庐 and SR CarnoSyn庐 in sports nutrition and wellness, visit and . For more information about our latest innovation, 罢谤颈叠蝉测苍鈩�, visit .
About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI鈥檚 comprehensive partnership approach offers a wide range of innovative nutritional products and services to clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please visit聽.
FAQ
What are the key clinical trial results for NAII's 罢谤颈叠蝉测苍鈩� supplement?
How does NAII's 罢谤颈叠蝉测苍鈩� technology improve beta-alanine absorption?
What is the recommended dosage of NAII's 罢谤颈叠蝉测苍鈩� compared to conventional beta-alanine?
Who are the target markets for NAII's 罢谤颈叠蝉测苍鈩� supplement?
